Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

IDH-mutant glioma

What is next, and who is running it?

Programs by company or class, across phase, filing, approval, and a stop.

A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.

Include Phase 1
ClassNone selected

11 of 15 programs on this matrix

Phase 2Phase 3FiledApprovedDiscontinued
alkylating chemotherapy2 programs
ATR inhibitor (ATRX-altered)1 program
Tuvusertib

Registry, Sep 2028

Dosing n/r

ATR inhibitor (ATRX-altered) · GEINO

mutant IDH1 inhibitor2 programs
mutant IDH1/IDH2 inhibitor2 programs
Vorasidenib

SNO 2026: INDIGO 41.6-month, seizure/QoL, real-world grade 2 and 3, Nov 12, 2026

once daily, oral

mutant IDH1/IDH2 inhibitor · Servier

PARP inhibitor1 program
Olaparib

Registry, Jan 2027

twice daily, oral

PARP inhibitor · Hospices Civils de Lyon (OLAGLI)

PD-1 antibody1 program
Nivolumab

Phase 2

Dosing n/r

PD-1 antibody · National Cancer Institute

peptide vaccine1 program
retinoid plus PD-1 antibody1 program